Skip to main content
Erschienen in: Supportive Care in Cancer 2/2013

01.02.2013 | Original Article

Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience

verfasst von: B. E. Kiely, G. McCaughan, S. Christodoulou, P. J. Beale, P. Grimison, J. Trotman, M. H. N. Tattersall, M. R. Stockler

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We sought the attitudes of people with a cancer experience to using best case, worst case, and typical scenarios for survival to explain life expectancy.

Methods

Oncology clinic attendees and Breast Cancer Network Australia (BCNA) members completed a survey describing two formats for explaining life expectancy to a hypothetical patient with advanced cancer—providing either three scenarios for survival or just the median survival time.

Results

Characteristics of the 505 respondents from outpatient clinics (n = 251) and BCNA (n = 254) were median age of 58 years, female 74 %, and breast primary 64 %. More respondents agreed that explaining three scenarios (vs. median survival) would make sense (93 vs. 75 %), be helpful (93 vs. 69 %), convey hope (68 vs. 44 %), and reassure (60 vs. 40 %), while fewer respondents agreed that explaining three scenarios (vs. median survival) would upset people (24 vs. 36 %); all p values < 0.001. Most respondents agreed that each scenario should be presented: best case 89 %, worst case 82 %, and typical 92 %. For information about their own prognosis, 88 % preferred all three scenarios and 5 % a single estimate of the median. Respondents with higher education were more likely to agree that presenting three scenarios would be helpful (95 vs. 90 %, p = 0.05). Respondents with breast cancer were more likely to agree that explaining three scenarios would upset people (31 vs. 13 %, p < 0.001).

Conclusions

Most respondents judged presentation of best case, worst case, and typical scenarios preferable and more helpful and reassuring than presentation of just the median survival time when explaining life expectancy to patients with advanced cancer.
Literatur
1.
Zurück zum Zitat Hagerty RG, Butow PN, Ellis PA et al (2004) Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721–1730PubMedCrossRef Hagerty RG, Butow PN, Ellis PA et al (2004) Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721–1730PubMedCrossRef
2.
Zurück zum Zitat Innes S, Payne S (2009) Advanced cancer patients' prognostic information preferences: a review. Palliat Med 23:29–39PubMedCrossRef Innes S, Payne S (2009) Advanced cancer patients' prognostic information preferences: a review. Palliat Med 23:29–39PubMedCrossRef
3.
Zurück zum Zitat Hancock K, Clayton JM, Parker SM et al (2007) Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review. Palliat Med 21:507–517PubMedCrossRef Hancock K, Clayton JM, Parker SM et al (2007) Truth-telling in discussing prognosis in advanced life-limiting illnesses: a systematic review. Palliat Med 21:507–517PubMedCrossRef
4.
Zurück zum Zitat Anderlik MR, Pentz RD, Hess KR (2000) Revisiting the truth-telling debate: a study of disclosure practices at a major cancer center. J Clin Ethics 11:251–259PubMed Anderlik MR, Pentz RD, Hess KR (2000) Revisiting the truth-telling debate: a study of disclosure practices at a major cancer center. J Clin Ethics 11:251–259PubMed
5.
Zurück zum Zitat Gordon EJ, Daugherty CK (2003) 'Hitting you over the head': oncologists' disclosure of prognosis to advanced cancer patients. Bioeth 17:142–168CrossRef Gordon EJ, Daugherty CK (2003) 'Hitting you over the head': oncologists' disclosure of prognosis to advanced cancer patients. Bioeth 17:142–168CrossRef
6.
Zurück zum Zitat Stockler MR, Tattersall MH, Boyer MJ et al (2006) Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208–212PubMedCrossRef Stockler MR, Tattersall MH, Boyer MJ et al (2006) Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208–212PubMedCrossRef
7.
Zurück zum Zitat Kiely BE, Tattersall MH, Stockler MR (2010) Certain death in uncertain time: informing hope by quantifying a best case scenario. J Clin Oncol 28:2802–2804PubMedCrossRef Kiely BE, Tattersall MH, Stockler MR (2010) Certain death in uncertain time: informing hope by quantifying a best case scenario. J Clin Oncol 28:2802–2804PubMedCrossRef
8.
Zurück zum Zitat Kiely BE, Alam M, Blinman P et al (2012) Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. Lung Cancer (in press) Kiely BE, Alam M, Blinman P et al (2012) Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. Lung Cancer (in press)
9.
Zurück zum Zitat Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:456–463PubMedCrossRef Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:456–463PubMedCrossRef
10.
Zurück zum Zitat Barnett MM (2006) Does it hurt to know the worst?—psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psychooncology 15:44–55PubMedCrossRef Barnett MM (2006) Does it hurt to know the worst?—psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psychooncology 15:44–55PubMedCrossRef
11.
Zurück zum Zitat Tattersall MH, Gattellari M, Voigt K, Butow PN (2002) When the treatment goal is not cure: are patients informed adequately? Support Care Cancer 10:314–321PubMedCrossRef Tattersall MH, Gattellari M, Voigt K, Butow PN (2002) When the treatment goal is not cure: are patients informed adequately? Support Care Cancer 10:314–321PubMedCrossRef
12.
Zurück zum Zitat Kaplowitz SA, Campo S, Chiu WT (2002) Cancer patients' desires for communication of prognosis information. Health Commun 14:221–241PubMedCrossRef Kaplowitz SA, Campo S, Chiu WT (2002) Cancer patients' desires for communication of prognosis information. Health Commun 14:221–241PubMedCrossRef
Metadaten
Titel
Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience
verfasst von
B. E. Kiely
G. McCaughan
S. Christodoulou
P. J. Beale
P. Grimison
J. Trotman
M. H. N. Tattersall
M. R. Stockler
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1526-4

Weitere Artikel der Ausgabe 2/2013

Supportive Care in Cancer 2/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.